Xtant Medical Ownership
| XTNT Stock | USD 0.54 0.06 12.50% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 135 M | Current Value 134 M | Avarage Shares Outstanding 46.7 M | Quarterly Volatility 50.8 M |
Xtant |
Xtant Stock Ownership Analysis
About 70.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.75. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Xtant Medical Holdings recorded a loss per share of 0.12. The entity last dividend was issued on the 14th of February 2018. The firm had 1:12 split on the 14th of February 2018. Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. Xtant Medical operates under Medical Devices classification in the United States and is traded on AMEX Exchange. It employs 116 people. For more information please call Sean Browne at 406 388 0480 or visit https://www.xtantmedical.com.Besides selling stocks to institutional investors, Xtant Medical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Xtant Medical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Xtant Medical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Xtant Medical Quarterly Liabilities And Stockholders Equity |
|
About 8.0% of Xtant Medical Holdings are currently held by insiders. Unlike Xtant Medical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Xtant Medical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Xtant Medical's insider trades
Xtant Medical Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xtant Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xtant Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xtant Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xtant Medical Outstanding Bonds
Xtant Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xtant Medical Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xtant bonds can be classified according to their maturity, which is the date when Xtant Medical Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xtant Stock Analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.